$PFSA

Profusa (PFSA) CFO converts $1.29M note into 302K shares at $4.28

Profusa (PFSA) CFO Fred Knechtel converted a $1.29M note into 302K shares at $4.28 each, following a 1-for-4 reverse stock split. The conversion occurred on August 12, 2026, under a Note Modification and Conversion Agreement. Knechtel, through NorthView Sponsor I LLC, now indirectly holds 302K shares.

Original reporting
Published Aug 20, 2026, 12:41 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 1:44 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$PFSA
Neutral
medium confidence
Mentioned
$PFSA
Relevance
5/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$PFSANeutralLow
01

Why it matters

The transaction modestly increases insider holdings while slightly diluting existing shareholders; likely minimal price movement.

02

Market read

Primary disclosure of an insider conversion; relevance limited to PFSA investors.

03

What to watch

Potential future financing needs if cash burn remains high.

Relevance 5/10Novelty 5/10Timing: post‑conversion Aug 12 2026

Background

Form 4 filing discloses insider conversion of a convertible promissory note into common stock after a 1‑for‑4 reverse split.

Company-level read

Ticker impact

$PFSANeutralMedium confidence
Context

CFO converted a $1.29M convertible note into 301,991 post‑split shares, increasing insider-held stock and diluting existing shareholders.

Expected impact

Minor downward pressure due to dilution, offset by insider confidence.

Evidence & confidence

Conversion size is small relative to market cap; insider stake remains minimal.

Market effects

Limited; reflects typical micro‑cap financing activity.

None

None

Counterpoint

The dilution could be viewed as a negative catalyst for short‑term traders.

Key entities

  • Profusa, Inc.

    Micro‑cap biotech listed on NASDAQ under PFSA.

  • Fred S. Knechtel

    Chief Financial Officer of Profusa, acting as manager of NorthView Sponsor I LLC.

Related articles

$PFSALow

Profusa, Inc. (PFSA): Results of Operations and Financial Condition

Profusa, Inc. (PFSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of w

$FDMTMed

Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

$PFSAMedAI 8/10

PFSA Stock Falls 19% Amid Diagnostics Acquisition News

Profusa (PFSA) said it signed a non-binding term sheet to acquire a privately held commercial diagnostics and toxicology testing company. The target estimates 2025 net revenues of about $111 million. Profusa would issue shares equal to 19.99% plus non-voting convertible preferred stock, subject to approval, and expects about $7 million financing via convertible notes. PFSA shares fell sharply after the news.